홈MCP워크벤치Skills
홈워크벤치알림마이페이지
llms.txt · MCP 가이드개인정보처리방침 · 이용약관 · 지원v1.8.3
  1. 홈
  2. /화합물

레시뉴라드

Lesinurad

HCID 53465279
새 반응
인쇄
기본 정보개요이름 및 식별자물성안전 및 규제화학 및 산업관련 반응화합물 노트
부분 구조 검색유사 구조 찾기

기본 정보

CAS
1890222-25-9
표준 SMILES
O=C(O)CSc1nnc(Br)n1-c1ccc(C2CC2)c2ccccc12
InChIKey
FGQFOYHRJSUHMR-UHFFFAOYSA-N
분자식
C17H14BrN3O2S
평균 분자량
404.3 g/mol
단동위원소 질량
402.99901

개요

Lesinurad is a member of the class of triazoles that is [(3-bromo-1,2,4-triazol-5-yl)sulfanyl]acetic acid substituted at position 1 of the triazole ring by a 4-cyclopropylnaphthalen-1-yl group. Used for treatment of gout. It has a role as a uricosuric drug. It is a monocarboxylic acid, a member of naphthalenes, an aryl sulfide, a member of triazoles, an organobromine compound and a member of cyclopropanes.

이름 및 식별자

우선 이름
Lesinurad
IUPAC
2-[[5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-1,2,4-triazol-3-yl]sulfanyl]acetic acid
현지명
레시뉴라드
영어명
RDEA 594
분자식
C17H14BrN3O2S
분자량
404.28

이름 및 동의어

LESINURAD878672-00-5RDEA594ZurampicRDEA 594RDEA-59409ERP08I3W2-[[5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-1,2,4-triazol-3-yl]sulfanyl]acetic acidCHEBI:90929DUZALLO COMPONENT LESINURADDTXSID2010260912-{[5-broMo-4-(4-cyclopropylnaphthalen-1-yl)-4H-1,2,4-triazol-3-yl]sulfanyl}acetic acid
이름 더 보기
레시뉴라드LesinurdResinadRescindRecinardReginaldResinardLesinurasLesurinad
{[5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-4H-1,2,4-triazol-3-yl]sulfanyl}acetic acidlesinuradum((5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-4H-1,2,4-triazol-3-yl)sulfanyl)acetic acid2-((5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-1,2,4-triazol-3-yl)sulfanyl)acetic acid2-((5-BROMO-4-(4-CYCLOPROPYLNAPHTHALEN-1-YL)-4H-1,2,4-TRIAZOL-3-YL)SULFANYL)ACETIC ACIDRefChem:56326M04AB05DTXCID901510348

데이터베이스 식별자

CAS
1890222-25-9、1890222-26-0、878672-00-5

물성

구조 계산 물성

XLogP
4.7
극성 표면적
93.3 Ų
수소 결합 공여자 수
1
수소 결합 수용자 수
5
회전 가능 결합 수
5
무거운 원자 수
24
형식 전하
0
복잡도
479

실험 및 물리화학적 성질

DrugsPharmaceuticals -> Listed in ZINC15
Human Drugs · 2건

FDA approved drugs -> Active ingredient

FDA approved drugs -> Active ingredient

물리화학적 성질

녹는점
171 oC · >171oC (dec.)
끓는 점
643.7 · 643.7±65.0 °C(Predicted)
밀도
1.72 · 1.72±0.1 g/cm3(Predicted)
저장 조건
-20 °C · -20°C Freezer, Under inert atmosphere
용해도
DMSO(약간 용해됨), 메탄올(약간 용해됨, 가열)
산도 계수 (pKa)
2.91 · 2.91±0.10(Predicted)
물리적 상태
고체
색상
흰색에서 황백색까지
InChI
InChI=1S/C17H14BrN3O2S/c18-16-19-20-17(24-9-15(22)23)21(16)14-8-7-11(10-5-6-10)12-3-1-2-4-13(12)14/h1-4,7-8,10H,5-6,9H2,(H,22,23)
InChIKey
FGQFOYHRJSUHMR-UHFFFAOYSA-N
SMILES
C(O)(=O)CSC1N(C2=C3C(C=CC=C3)=C(C3CC3)C=C2)C(Br)=NN=1

안전 및 규제

안전 정보는 참고용이며, 공급업체의 물질안전보건자료(SDS), 관련 법규 및 전문가 평가를 대체하지 않습니다.

GHS 분류

GHS Classification · 4건

Warning

H302 (100%): Harmful if swallowed [Warning Acute toxicity, oral]

P264, P270, P301+P317, P330, and P501 (click each P-code to see the statement)

Aggregated GHS information provided per 5 reports by companies from 2 notifications to the ECHA C&L Inventory.

유해성 정보

Hazard Classes and CategoriesAcute Tox. 4 (100%)

독성 정보

Hepatotoxicity · 1건

In large clinical trials, serum enzyme elevations were rare during lesinurad therapy and no more common than with placebo, and no instances of clinically apparent liver injury attributable to lesinurad were reported. Clinical experience with lesinurad therapy has been limited, but there have yet to be reports of clinically apparent liver injury attributable to its use.

안전 데이터

wgk
WGK 3
스토리지 클래스
11 - Combustible Solids

화학 및 산업

약리 정보

ATC Code · 2건

M - Musculo-skeletal system

QM - Musculo-skeletal system

Protein BindingLesinurad is extensively bound to proteins in plasma (greater than 98%), mainly to albumin.
PharmacodynamicsDose-dependent reductions in serum uric acid levels and increases in urinary uric acid excretion have been observed following single and multiple oral doses of lesinurad.
Mechanism of Action · 1건

Lesinurad inhibits the activity of uric acid transporter 1 (URAT1) and organic anion transporter 4 (OAT4). URAT1 is a major transporter enzyme responsible for reuptake of uric acid from the renal tubules; inhibition of URAT1 function thereby increases excretion of uric acid.

Metabolism/MetabolitesLesinurad undergoes oxidative metabolism mainly via the polymorphic cytochrome P450 CYP2C9 enzyme.
FDA Pharmacological Classification · 6건

09ERP08I3W

LESINURAD

Established Pharmacologic Class [EPC] - Urate Transporter 1 Inhibitor

Mechanisms of Action [MoA] - Urate Transporter 1 Inhibitors

Mechanisms of Action [MoA] - Cytochrome P450 3A Inducers

Lesinurad is an Urate Transporter 1 Inhibitor. The mechanism of action of lesinurad is as an Urate Transporter 1 Inhibitor and Cytochrome P450 3A Inducer.

MeSH Pharmacological Classification · 2건

Agents that increase uric acid excretion by the kidney (URICOSURIC AGENTS), decrease uric acid production (antihyperuricemics), or alleviate the pain and inflammation of acute attacks of gout.

Gout suppressants that act directly on the renal tubule to increase the excretion of uric acid, thus reducing its concentrations in plasma.

Absorption, Distribution and Excretion · 3건

관련 반응

87건
반응 기록 만들기
HRID 38744 반응식
HRID 38744반응물로
HRID 38745 반응식
HRID 38745생성물로
HRID 143474 반응식
HRID 143474반응물로
HRID 172212 반응식
HRID 172212생성물로
HRID 197994 반응식
HRID 197994반응물로
HRID 199579 반응식
HRID 199579반응물로
HRID 212933 반응식
HRID 212933생성물로
HRID 473266 반응식
HRID 473266생성물로
이전1 / 11 페이지

화합물 노트

이 페이지에서기본 정보개요이름 및 식별자물성안전 및 규제화학 및 산업관련 반응화합물 노트
PubChem CID
53465279
DTXSID
DTXSID201026091
ChEMBL
CHEMBL2105720
ChEBI
CHEBI:90929
UNII
09ERP08I3W、73WY698HZ7、Q59CAT99RS
EC Number
689-245-8
Nikkaji
J3.671.265A

Oral lesinurad is rapidly absorbed, reaching maximum plasma concentrations (Cmax) within 1–4 h following the administration a single 200 mg dose (in either the fed or fasted state).

Within 7 days following single dosing of radiolabeled lesinurad, 63% of administered radioactive dose was recovered in urine and 32% of administered radioactive dose was recovered in feces. Most of the radioactivity recovered in urine (> 60% of dose) occurred in the first 24 hours. Unchanged lesinurad in urine accounted for approximately 30% of the dose.

The mean steady state volume of distribution of lesinurad was approximately 20 L following intravenous dosing.

응용 분야 · 2건

개요Approved by the FDA late in 2015, lesinurad is an urate anion exchange transporter 1 (URAT1) inhibitor for use in the treatment of gout. Ardea Biosciences, which is a subsidiary of AstraZeneca, developed lesinurad to be used in a combination therapy with xanthine oxidase inhibitors for the treatment of hyperuricaemia associated with gout. The approval process is ongoing in several other countries across the globe, with the EMA Committee for Medicinal Products for Human Use giving lesinurad a positive opinion for use as an adjunctive therapy in combination with xanthine oxidase inhibitors to treat hyperuricaemia.

용도Lesinurad is used to synthesize febuxostat which is a non-purine analog inhibitor of xanthine oxidase. Febuxostat is approved by the European Medicines Agency and the US Food and Drug Administration for treating gout.

추가 설명

정의ChEBI: A member of the class of triazoles that is [(3-bromo-1,2,4-triazol-5-yl)sulfanyl]acetic acid substituted at position 1 of the triazole ring by a 4-cyclopropylnaphthalen-1-yl group. Used for treatment of gout.